Año 2019 / Volumen 111 / Número 4
Editorial
Characterizing specific subgroups in patients with NAFLD: overweight vs obese phenotype

253-255

DOI: 10.17235/reed.2019.6269/2019

Rosa Martín Mateos, Alina M. Allen,

Resumen
Non-alcoholic fatty liver disease (NAFLD) is increasingly recognized as the most common cause of chronic liver disease worldwide, with a global prevalence of 25.2%. The high burden of NAFLD extends beyond liver diseases, as patients are at risk of developing not only liver related conditions, including cirrhosis and hepatocellular carcinoma, but also cardiovascular complications associated to metabolic syndrome. The present special issue of The Spanish Journal of Gastroenterology (Revista Española de Enfermedades Digestivas) focusses on diverse key aspects of NAFLD, including characterization of fecal microbiota profiles, the role of bariatric endoscopy, evaluation of suitable pre-clinical models for NAFLD or differential epidemiological risk factors associated to NASH and fibrosis.
Share Button
Nuevo comentario
Comentarios
No hay comentarios para este artículo.
Bibliografía
[1] Younossi ZM, Koenig AB, Abdelatif D, et al. Global Epidemiology of Nonalcoholic Fatty Liver Disease—Meta-Analytic Assessment of Prevalence, Incidence, and Outcomes. Hepatology. 2016;64:73–84.
[2] Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67:73–84.
[3] Stepanova M, Rafiq N, Makhlouf H, et al. Predictors of All-Cause Mortality and Liver-Related Mortality in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD). Dig Dis Sci. 2013;58:3017–23.
[4] Allen AM, Therneau TM, Larson JJ, et al. Nonalcoholic fatty liver disease incidence and impact on metabolic burden and death: A 20 year-community study. Hepatology. 2018;67:1726–36.
[5] Golabi P, Paik J, Fukui N, et al. Patients With Lean Nonalcoholic Fatty Liver Disease Are Metabolically Abnormal and Have a Higher Risk for Mortality. Clin Diabetes. 2019;37:65–72.
[6] Ampuero J, Aller R, Gallego-Durán R, et al. The effects of metabolic status on non-alcoholic fatty liver disease-related outcomes, beyond the presence of obesity. Aliment Pharmacol Ther. 2018;48:1260–70.
[7] Aller R, Burgueño B, Sigüenza R, et al. Comparative study of overweight and obese patients with nonalcoholic fatty liver disease. Rev Esp Enfermedades Dig. 2019. doi: 10.17235/reed.2019.5926/2018
[8] Berzigotti A, Albillos A, Villanueva C, et al. Effects of an intensive lifestyle intervention program on portal hypertension in patients with cirrhosis and obesity: The SportDiet study. Hepatology. 2017;65:1293–305.
[9] Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, et al. Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. Gastroenterology. 2015;149:367–378
[10] Byrne CD, Targher G. EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. Diabetologia. 2016;59:1141–4.
[11] Esposito K, Kastorini CM, Panagiotakos DB, et al. Mediterranean diet and metabolic syndrome: An updated systematic review. Rev Endocr Metab Disord. 2013;14:255–63.
[12] Romaguera D, Norat T, Mouw T, et al. Adherence to the Mediterranean Diet Is Associated with Lower Abdominal Adiposity in European Men and Women. J Nutr. 2009;139:1728–37.
[13] Esposito K, Maiorino MI, Bellastella G, et al. A journey into a Mediterranean diet and type 2 diabetes: a systematic review with meta-analyses. BMJ Open. 2015;5:e008222.
[14] Trichopoulou A, Costacou T, Bamia C, et al. Adherence to a Mediterranean Diet and Survival in a Greek Population. N Engl J Med. 2003;348:2599–608.
[15] Baratta F, Pastori D, Polimeni L, et al. Adherence to Mediterranean Diet and Non-Alcoholic Fatty Liver Disease: Effect on Insulin Resistance. Am J Gastroenterol. 2017;112:1832–9.
[16] Trovato FM, Catalano D, Martines GF, et al. Mediterranean diet and non-alcoholic fatty liver disease. Clin Nutr. 2015;34:86–8.
[17] Sookoian S, Pirola CJ. Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology. 2011;53:1883–94.
[18] Valenti L, Fracanzani AL, Dongiovanni P, et al. Tumor necrosis factor α promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease. Gastroenterology. 2002;122:274–80.
[19] Kaser S. Adiponectin and its receptors in non-alcoholic steatohepatitis. Gut. 2005;54:117–21.
Artículos relacionados
Instrucciones para citar
Martín Mateos R, Allen A. Characterizing specific subgroups in patients with NAFLD: overweight vs obese phenotype. 6269/2019


Descargar en un gestor de citas

Descargue la cita de este artículo haciendo clic en uno de los siguientes gestores de citas:

Métrica
Este artículo ha sido visitado 651 veces.
Este artículo ha sido descargado 255 veces.

Estadísticas de Dimensions


Estadísticas de Plum Analytics

Ficha Técnica

Recibido: 08/03/2019

Aceptado: 11/03/2019

Prepublicado: 28/03/2019

Publicado: 04/04/2019

Tiempo de prepublicación: 20 días

Tiempo de edición del artículo: 27 días


Compartir
Este artículo aun no tiene valoraciones.
Valoración del lector:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
La REED es el órgano oficial de la Sociedad Española de Patología Digestiva, la SociedadEspañola de Endoscopia Digestiva y la Asociación Española de Ecografía Digestiva
Política de cookies Política de Privacidad Aviso Legal © Copyright 2023 y Creative Commons. Revista Española de Enfermedades Digestivas